Edition:
United States

Erytech Pharma SA (ERYP.OQ)

ERYP.OQ on NASDAQ Stock Exchange Global Select Market

18.49USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$18.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$30.48
52-wk Low
$18.28

Latest Key Developments (Source: Significant Developments)

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
Friday, 8 Dec 2017 01:52am EST 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.  Full Article

Erytech Pharma SA ADS debut about 14.7 pct above IPO price
Friday, 10 Nov 2017 09:55am EST 

Nov 10 (Reuters) - :Erytech Pharma SA ADS open at $26.68 in debut on the NASDAQ versus IPO price of $23.26 per ADS‍​‍​​.  Full Article

Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​
Friday, 10 Nov 2017 08:08am EST 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​.‍GLOBAL OFFERING COMPRISING AN OFFER OF 4.7 MILLION ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES​.IN ‍UNITED STATES, OFFERING PRICE OF $23.26 PER ADS​.‍PRIVATE PLACEMENT IN EUROPE (INCL. FRANCE) AND OTHER COUNTRIES (EXCLUDING. US AND CANADA) OF 0.7 MILLION ORDINARY SHARES AT OFFERING PRICE OF EUR 20 PER SHARE.‍LISTING ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL "ERYP"​.‍GLOBAL OFFERING FOR TOTAL GROSS PROCEEDS OF ABOUT $125 MILLION BEFORE DEDUCTING UNDERWRITING COMMISSIONS AND ESTIMATED EXPENSES PAYABLE BY CO​.‍CLOSING OF GLOBAL OFFERING EXPECTED ON OR ABOUT NOV 14, 2017​.‍FOLLOWING CLOSING COMPANY WILL HAVE ISSUED 5,374,033 ORDINARY SHARES (INCL. ADSS)​.  Full Article

Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​
Friday, 10 Nov 2017 02:18am EST 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS.SUSPENSION TO ALLOW FOR CONFIRMATION OF ALLOCATIONS TO INVESTORS & CO'S ADSS BEGINNING TRADING ON NASDAQ GLOBAL SELECT MARKET .‍SUSPENSION EFFECTIVE UNTIL A NEW COMMUNICATION IS RELEASED BY COMPANY​.‍TRADING ON REGULATED MARKET OF EURONEXT PARIS EXPECTED TO RESUME NOV 10, 2017 ABOUT 4:00 PM (CET)​.  Full Article

Erytech Pharma 9M net loss widens to 20.8 million euros
Tuesday, 7 Nov 2017 01:45am EST 

7 Nov(Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO.CASH AND CASH EQUIVALENTS OF EUR 80.3 MLN ON SEPT 30, VS 88.5 MLN ON JUNE 30.FINANCIAL RESULTS ARE IN LINE WITH STRATEGY FOR 2017.  Full Article

Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs
Monday, 6 Nov 2017 01:36pm EST 

Nov 6 (Reuters) - Erytech Pharma SA :Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing.Erytech Pharma SA says U.S. IPO price is expected to be between $23.00 and $24.00 per ADS.  Full Article

Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS
Friday, 6 Oct 2017 05:15pm EDT 

Oct 6 (Reuters) - Erytech Pharma Sa :Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing‍​.Erytech Pharma Sa says have applied to list ADSS on Nasdaq global market under symbol “ERYP”.Erytech Pharma Sa says Jefferies, Cowen, ODDO BHF and JPM Securities are underwriters to the IPO.Erytech Pharma Sa - proposed IPO price is an estimate solely for purpose of calculating SEC registration fee.  Full Article

Erytech reports determination of the recommended pivotal phase 3 dose of eryaspase in its U.S. Phase 1 study
Thursday, 28 Sep 2017 01:31am EDT 

Sept 28 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS DETERMINATION OF THE RECOMMENDED PIVOTAL PHASE 3 DOSE OF ERYASPASE IN ITS U.S. PHASE 1 STUDY IN FIRST LINE ADULT ALL.DOSE OF 100 U/KG WAS RECOMMENDED FOR FURTHER EVALUATION OF ERYASPASE IN PIVOTAL STUDY IN FIRST LINE ADULT ALL​.CO WILL ALSO POTENTIALLY INITIATE LAUNCH OF PIVOTAL PHASE 3 STUDY IN FIRST LINE ADULT ALL PATIENTS AT SAME DOSE LEVEL AS FOR PHASE 1.‍​.  Full Article

Erytech Pharma H1 net loss widens to ‍​14.0 million euros
Monday, 11 Sep 2017 12:31pm EDT 

Sept 11 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.‍SOLID CASH POSITION OF EUR 88.5 MILLION AS OF JUNE 30, 2017​.H1 OPERATING LOSS EUR ‍​14.2 MILLION VERSUS LOSS OF EUR 10.6 MILLION YEAR AGO.H1 NET LOSS EUR ‍​14.0 MILLION VERSUS LOSS OF EUR 10.3 MILLION YEAR AGO.H1 TOTAL OPERATING INCOME EUR ‍​ 1.8 MILLION VERSUS EUR 2.4 MILLION YEAR AGO.  Full Article

Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​
Friday, 8 Sep 2017 01:31am EDT 

Sept 8 (Reuters) - ERYTECH PHARMA SA : :COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​.COMPLETE RESULTS FOR PHASE 2B STUDY WITH ERYASPASE IN COMBINATION WITH CHEMOTHERAPY IN SECOND-LINE TREATMENT OF METASTATIC PANCREATIC CANCER‍​.A MEETING WITH THE US FDA IS SCHEDULED TO DISCUSS THE DESIGN OF A PHASE 3 STUDY‍​.  Full Article

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​